© Drug Hunter Inc. 2018-2023
Home > CC-92480
CRBN-based selective IKZF1/3 degrader
oral efficacy in lenalidomide-resist. xenograft
from phenotypic screen and optimization
J. Med. Chem., Mar. 4, 2020
Celgene, San Diego, CA
CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year